ABCC5 and hepatocellular carcinoma: A recent study using HuH-7, HepG2, and SK-Hep-1 cell lines has revealed that long-term administration of sorafenib activates the PI3K/AKT/Nrf2 pathway in HCC, which is necessary for the induction of ABCC5 expression by sorafenib.